NCT04343976

Pegylated Interferon Lambda Treatment for COVID-19

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Raymond Chung · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.

Detailed description

The study objective is to assess the efficacy of Pegylated Interferon Lambda (180 mcg) vs. placebo in inducting quantitative PCR negativity at day 7

Conditions

• COVID-19
• COVID

Interventions

Type	Name	Description
DRUG	Pegylated interferon lambda	180 mcg subcutaneous injection of pegylated interferon lambda

Timeline

• Start date: 2020-06-22
• Primary completion: 2021-07-30
• Completion: 2021-07-30
• First posted: 2020-04-14
• Last updated: 2022-07-21
• Results posted: 2022-07-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study